dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

Liran Holtzman, Mor Moskovitz, Damien Urban, Hovav Nechushtan, S. Keren, Daniel Reinhorn, Mira Wollner, Sameh Daher, Yakir Rottenberg, Yulia Rovitzky, Tzippy Shochat, Jair Bar, Elizabeth Dudnik